Literature DB >> 21596319

Assessment of echo-attenuated plaque by optical coherence tomography and its impact on post-procedural creatine kinase-myocardial band elevation in elective stent implantation.

Tetsumin Lee1, Tsunekazu Kakuta, Taishi Yonetsu, Kentaro Takahashi, Ginga Yamamoto, Yoshito Iesaka, Hideomi Fujiwara, Mitsuaki Isobe.   

Abstract

OBJECTIVES: This study examined morphological characteristics of echo-attenuated plaques by optical coherence tomography (OCT) and evaluated their influence on creatine kinase-myocardial band (CK-MB) elevation after percutaneous coronary intervention (PCI) in patients with elective stent implantation.
BACKGROUND: Recent intravascular ultrasound studies have described atherosclerotic plaques with echo attenuation (EA) without associated bright echoes that are correlated with no-reflow phenomenon after PCI.
METHODS: We studied 135 native de novo culprit coronary lesions in 135 patients with normal pre-PCI CK-MB levels (28 with unstable angina; 107 with stable angina) who underwent intravascular ultrasound and OCT examinations before elective stent implantation. The lesions were divided into 2 groups based on the presence or absence of EA, and OCT findings were compared. We then determined predictors of post-PCI CK-MB elevation.
RESULTS: EA was found in 47 (34.8%) lesions and was associated with the presence of OCT-derived thin-capped fibroatheroma, ruptured plaques, greater lipid content, intravascular ultrasound-derived large reference and plaque area, lesion eccentricity, and microcalcification. Elevated CK-MB levels were observed in 36 (26.7%) lesions, and significantly more frequently in lesions with EA than without. In multivariable analysis, EA (odds ratio [OR]: 3.49; 95% confidence interval [CI]: 1.53 to 7.93; p = 0.003) and OCT-derived ruptured plaque (OR: 2.92; 95% CI: 1.21 to 7.06; p = 0.017) were independent predictors of post-PCI CK-MB elevation.
CONCLUSIONS: Atherosclerotic plaques with EA were associated with characteristics considered to be high risk or unstable. OCT examination showed an additive predictive value to the presence of EA for post-PCI CK-MB elevation.
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21596319     DOI: 10.1016/j.jcin.2010.12.013

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  10 in total

1.  Pericoronary adipose tissue ratio is a stronger associated factor of plaque vulnerability than epicardial adipose tissue on coronary computed tomography angiography.

Authors:  Ryo Okubo; Rine Nakanishi; Mikihito Toda; Daiga Saito; Ippei Watanabe; Takayuki Yabe; Hideo Amano; Tatsushi Hirai; Takanori Ikeda
Journal:  Heart Vessels       Date:  2017-02-22       Impact factor: 2.037

2.  Long-term prognostic impact of the attenuated plaque in patients with acute coronary syndrome.

Authors:  Hiroyuki Okura; Toru Kataoka; Minoru Yoshiyama; Junichi Yoshikawa; Kiyoshi Yoshida
Journal:  Heart Vessels       Date:  2014-09-03       Impact factor: 2.037

3.  Impact of attenuated plaques on TIMI grade flow and clinical outcomes of coronary artery disease patients: a systematic review and meta analysis.

Authors:  Ruofei Jia; Xiaolu Nie; Hong Li; Huagang Zhu; Lianmei Pu; Xiang Li; Jing Han; Duo Yang; Shuai Meng; Zening Jin
Journal:  J Thorac Dis       Date:  2016-03       Impact factor: 2.895

4.  The Predictive Value of Baseline Target Lesion SYNTAX Score for No-Reflow during Urgent Percutaneous Coronary Intervention in Acute Myocardial Infarction.

Authors:  Guofeng Gao; Han Xu; Dong Zhang; Chenxi Song; Changdong Guan; Bo Xu; Dong Yin; Kefei Dou
Journal:  J Interv Cardiol       Date:  2021-08-04       Impact factor: 2.279

5.  Attenuated-Signal Plaque Progression Predicts Long-Term Mortality After Heart Transplantation: IVUS Assessment of Cardiac Allograft Vasculopathy.

Authors:  Kozo Okada; William F Fearon; Helen Luikart; Hideki Kitahara; Kyuhachi Otagiri; Shigemitsu Tanaka; Takumi Kimura; Paul G Yock; Peter J Fitzgerald; Alan C Yeung; Hannah A Valantine; Kiran K Khush; Yasuhiro Honda
Journal:  J Am Coll Cardiol       Date:  2016-07-26       Impact factor: 24.094

6.  Impact of thin-cap fibroatheroma on predicting deteriorated coronary flow during interventional procedures in acute as well as stable coronary syndromes: insights from optical coherence tomography analysis.

Authors:  Tadatsugu Gamou; Kenji Sakata; Takao Matsubara; Toshihiko Yasuda; Kenji Miwa; Masaru Inoue; Honin Kanaya; Tetsuo Konno; Kenshi Hayashi; Masaaki Kawashiri; Masakazu Yamagishi
Journal:  Heart Vessels       Date:  2014-07-19       Impact factor: 2.037

Review 7.  Spontaneous and procedural plaque embolisation in native coronary arteries: pathophysiology, diagnosis, and prevention.

Authors:  Giovanni Luigi De Maria; Niket Patel; George Kassimis; Adrian P Banning
Journal:  Scientifica (Cairo)       Date:  2013-12-19

Review 8.  Coronary plaque morphology on multi-modality imagining and periprocedural myocardial infarction after percutaneous coronary intervention.

Authors:  Akira Sato; Kazutaka Aonuma
Journal:  Int J Cardiol Heart Vasc       Date:  2016-03-17

9.  Impact of high-density lipoprotein 3 cholesterol subfraction on periprocedural myocardial injury in patients who underwent elective percutaneous coronary intervention.

Authors:  Kazuhiro Harada; Ryosuke Kikuchi; Susumu Suzuki; Akihito Tanaka; Toshijiro Aoki; Naoki Iwakawa; Hiroki Kojima; Kenshi Hirayama; Takayuki Mitsuda; Takuya Sumi; Yosuke Negishi; Hideki Ishii; Toyoaki Murohara
Journal:  Lipids Health Dis       Date:  2018-02-02       Impact factor: 3.876

10.  Culprit Plaque Characteristics in Patients With Sleep-Disordered Breathing Undergoing Percutaneous Coronary Intervention: An Intravascular Ultrasound Study.

Authors:  Hideki Wada; Tomotaka Dohi; Takatoshi Kasai; Shoichiro Yatsu; Ryo Naito; Yoshiteru Kato; Iwao Okai; Hiroshi Iwata; Kikuo Isoda; Shinya Okazaki; Katsumi Miyauchi; Hiroyuki Daida
Journal:  J Am Heart Assoc       Date:  2018-10-02       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.